Carotid endarterectomy surgery
This article was originally published in The Gray Sheet
Executive Summary
Preliminary feedback from a trial of EndoTex's NextStent carotid stent with Boston Scientific's FilterWire EX embolic protection device is "promising," according to Boston Scientific Peripheral Interventions Business President Matthew Jenusaitis. CABERNET recently completed enrollment of 450 patients ineligible for carotid endarterectomy surgery at 15 U.S. centers, the firms announced March 25. Boston Scientific will be the exclusive distributor for NextStent and has the option to buy EndoTex under the terms of a May 2003 agreement extension (1"The Gray Sheet" May 26, 2003, p. 26)...
You may also be interested in...
Boston Scientific Extends EndoTex Purchase Option; NexStent Evaluated
EndoTex Interventional Systems is planning an early 2004 launch of its self-expanding NexStent carotid stent outside the U.S., using Boston Scientific as exclusive distributor under an extended agreement between the firms
Day One Springs Into Commercial Action With Ojemda Approval
The company is targeting around 200 centers that treat the vast majority of the few thousand pediatric low-grade glioma patients who are candidates for the RAF-targeting drug.
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.